Literature DB >> 14962506

Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds.

Gianfranco Natale1, Gloria Lazzeri, Valter Lubrano, Rocchina Colucci, Cristina Vassalle, Matteo Fornai, Corrado Blandizzi, Mario Del Tacca.   

Abstract

This study investigated the mechanisms involved in the protective actions exerted by lansoprazole against experimental gastric injury. Following the intraluminal injection of ethanol-HCl, the histomorphometric analysis of rat gastric sections demonstrated a pattern of mucosal lesions associated with a significant increase in the mucosal contents of malondialdehyde and 8-iso-prostaglandin F(2alpha) (indices of lipid peroxidation), as well as a decrease in the levels of mucosal sulfhydryl compounds, assayed as reduced glutathione (GSH). Pretreatment with lansoprazole 90 micromol/kg, given intraduodenally as single dose or once daily by intragastric route for 8 days, significantly prevented ethanol-HCl-induced gastric damage. The concomitant changes in the mucosal levels of malondialdehyde, 8-iso-prostaglandin F(2alpha) and GSH elicited by ethanol-HCl were also counteracted by lansoprazole. In separate experiments, performed on animals undergoing 2-h pylorus ligation, lansoprazole did not enhance the concentration of prostaglandin E(2), bicyclo-prostaglandin E(2), or nitric oxide (NO) metabolites into gastric juice. Western blot analysis revealed the expression of both type 1 and 2 cyclooxygenase (COX) isoforms in the gastric mucosa of pylorus-ligated rats. These expression patterns were not significantly modified by single-dose or repeated treatment with lansoprazole. Lansoprazole also exhibited direct antioxidant properties by reducing 8-iso-prostaglandin F(2alpha) generation in an in vitro system where human native low-density lipoproteins were subjected to oxidation upon exposure to CuSO(4). The present results suggest that the protective effects of lansoprazole can be ascribed to a reduction of gastric oxidative injury, resulting in an increased bioavailability of mucosal sulfhydryl compounds. It is also proposed that lansoprazole does not exert modulator effects on the gastric expression of COX isoforms as well as on the activity of NO pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962506     DOI: 10.1016/j.taap.2003.10.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  19 in total

Review 1.  Present status and strategy of NSAIDs-induced small bowel injury.

Authors:  Kazuhide Higuchi; Eiji Umegaki; Toshio Watanabe; Yukiko Yoda; Eijiro Morita; Mitsuyuki Murano; Satoshi Tokioka; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-07-01       Impact factor: 7.527

2.  Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.

Authors:  Corrado Blandizzi; Matteo Fornai; Rocchina Colucci; Gianfranco Natale; Valter Lubrano; Cristina Vassalle; Luca Antonioli; Gloria Lazzeri; Mario Del Tacca
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Renoprotective effect of lansoprazole in streptozotocin-induced diabetic nephropathy in wistar rats.

Authors:  Rupinder Kaur; Rupinder Kaur Sodhi; Neha Aggarwal; Jaspreet Kaur; Upendra K Jain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-10-16       Impact factor: 3.000

4.  Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage.

Authors:  M Fornai; G Natale; R Colucci; M Tuccori; G Carazzina; L Antonioli; S Baldi; V Lubrano; A Abramo; C Blandizzi; M Del Tacca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-04       Impact factor: 3.000

5.  Geraniol-a flavoring agent with multifunctional effects in protecting the gastric and duodenal mucosa.

Authors:  Katharinne Ingrid Moraes de Carvalho; Flavia Bonamin; Raquel Cássia Dos Santos; Larissa Lucena Périco; Fernando Pereira Beserra; Damião Pergentino de Sousa; José Maria Barbosa Filho; Lucia Regina Machado da Rocha; Clelia Akiko Hiruma-Lima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-17       Impact factor: 3.000

6.  Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine.

Authors:  Cristina Pozzoli; Alessandro Menozzi; Daniela Grandi; Elvira Solenghi; Maria C Ossiprandi; Chiara Zullian; Simone Bertini; Giulia M Cavestro; Gabriella Coruzzi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-07       Impact factor: 3.000

7.  Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin.

Authors:  O Pastoris; M Verri; F Boschi; O Kastsiuchenka; B Balestra; F Pace; M Tonini; G Natale
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-11       Impact factor: 3.000

8.  Does Helicobacter pylori-induced inflammation of gastric mucosa determine the severity of symptoms in functional dyspepsia?

Authors:  Ebru Turkkan; Ihsan Uslan; Gursel Acarturk; Nevin Topak; Ahmet Kahraman; Fatma Husniye Dilek; Yusuf Akcan; Ozcan Karaman; Mehmet Colbay; Seref Yuksel
Journal:  J Gastroenterol       Date:  2009-01-22       Impact factor: 7.527

9.  Prevention of NSAID-Induced Small Intestinal Mucosal Injury: Prophylactic Potential of Lansoprazole.

Authors:  Kazuhide Higuchi; Yukiko Yoda; Kikuko Amagase; Shinichi Kato; Satoshi Tokioka; Mitsuyuki Murano; Koji Takeuchi; Eiji Umegaki
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

10.  A possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats.

Authors:  Ho-Jae Lee; Young-Min Han; Eun-Hee Kim; Yoon-Jae Kim; Ki-Baik Hahm
Journal:  BMC Gastroenterol       Date:  2012-10-16       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.